This article is more than 5 years old. Information may no longer be current.

Could a common cold virus improve bladder cancer treatment? Read the week’s top stories in hematology/oncology

A novel therapeutic treatment using a common cold virus could be effective in patients with nonmuscle-invasive bladder cancer, and breast cancer history was associated with an increased risk for congestive heart failure later in life.

These and more were the top stories in hematology and oncology last week.

Common cold virus could transform bladder cancer treatment

A novel therapeutic approach that involves the oncolytic virus coxsackievirus showed potential among a small cohort of patients with nonmuscle-invasive bladder cancer, according to study findings published in Clinical Cancer Research. Read more.

Younger breast cancer survivors at higher risk for late congestive heart failure

Young survivors of breast cancer face higher risk for late congestive heart failure than their counterparts without cancer, according to study results published in Cancer. Read more.

Three-year survival update confirms efficacy of pembrolizumab in non-small cell lung cancer

BARCELONA — First-line pembrolizumab monotherapy conferred a durable long-term OS benefit compared with chemotherapy for patients with metastatic, PD-L1-expressing non-small cell lung cancer, according to 3-year survival results of the KEYNOTE-024 trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. Read more.

Dexrazoxane may reduce cardiotoxicity from breast cancer treatment

Dexrazoxane reduced the risk for cardiac events and clinical heart failure among women with breast cancer who underwent anthracycline chemotherapy, according to results of a systematic review and meta-analysis published in JACC: Cardio-Oncology. Read more.

Atezolizumab extends overall survival for PD-L1-selected patients with non-small cell lung cancer

BARCELONA — Atezolizumab significantly prolonged OS compared with platinum-based chemotherapy for patients with newly diagnosed non-small cell lung cancer whose tumors expressed high levels of PD-L1, according to an interim survival analysis from the phase 3 IMpower110 study presented at European Society for Medical Oncology Congress. Read more.